KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non Operating Income (2016 - 2025)

Supernus Pharmaceuticals has reported Other Non Operating Income over the past 15 years, most recently at $2.0 million for Q4 2025.

  • Quarterly Other Non Operating Income fell 59.35% to $2.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $13.3 million through Dec 2025, down 18.21% year-over-year, with the annual reading at $13.3 million for FY2025, 18.21% down from the prior year.
  • Other Non Operating Income was $2.0 million for Q4 2025 at Supernus Pharmaceuticals, down from $2.3 million in the prior quarter.
  • Over five years, Other Non Operating Income peaked at $14.7 million in Q1 2022 and troughed at -$21.5 million in Q4 2021.
  • The 5-year median for Other Non Operating Income is $2.7 million (2021), against an average of $2.4 million.
  • Year-over-year, Other Non Operating Income tumbled 65.37% in 2021 and then soared 285.57% in 2022.
  • A 5-year view of Other Non Operating Income shows it stood at -$21.5 million in 2021, then skyrocketed by 111.14% to $2.4 million in 2022, then dropped by 17.25% to $2.0 million in 2023, then surged by 150.6% to $5.0 million in 2024, then crashed by 59.35% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for SUPN's Other Non Operating Income are $2.0 million (Q4 2025), $2.3 million (Q3 2025), and $4.5 million (Q2 2025).